Seaport Therapeutics Advances GlyphAgo into Phase 2 Trials After Positive Phase 1 Data
Event summary
- Seaport Therapeutics reported positive multiple-ascending dose (MAD) data from its Phase 1 proof-of-concept trial of GlyphAgo™ in healthy volunteers.
- GlyphAgo demonstrated a favorable safety, tolerability, and pharmacokinetic (PK) profile, with no liver-related adverse events observed.
- Seaport plans to initiate two parallel Phase 2 trials for GlyphAgo in patients with generalized anxiety disorder (GAD) in late 2026 and early 2027.
- The Phase 2a trial will focus on sleep architecture in GAD patients with sleep disturbance, while the Phase 2b trial will evaluate efficacy and safety in GAD patients.
The big picture
Seaport Therapeutics' advancement of GlyphAgo into Phase 2 trials marks a significant milestone in the development of novel neuropsychiatric medicines. The positive Phase 1 data underscores the potential of the Glyph platform to overcome key limitations of existing therapies, addressing a substantial unmet need in the treatment of generalized anxiety disorder. The strategic focus on enhancing lymphatic absorption and avoiding first-pass liver metabolism positions Seaport to potentially deliver a differentiated therapeutic option in a market that has seen limited innovation in nearly two decades.
What we're watching
- Clinical Development
- How the Phase 2 trials will validate GlyphAgo's efficacy and safety in GAD patients, potentially positioning it as a leading treatment option.
- Regulatory Pathway
- Whether the Phase 2b trial will serve as a registration-enabling study, accelerating GlyphAgo's path to market approval.
- Market Differentiation
- The pace at which Seaport can differentiate GlyphAgo from existing treatments, leveraging its Glyph platform to enhance bioavailability and reduce side effects.
Related topics